Specialist · Montreal, QC
Amplitude Ventures
Full-stack precision medicine VC investing at the intersection of biology and AI
- Cheque
- $5M to $30M
- Role
- Can lead a round
- Pace
- Actively deploying
- Kind
- Specialist
- Based in
- Montreal, QC
- Vehicle size
- $263M
- Founded
- 2019
- Works in
- EN + FR
- Last deal seen
- April 2026
- Stages
- Pre-seed, Seed, Series A, Series B and later
- Sectors
- Health and biotech
Their thesis, in full
Canadian specialist in precision medicine, spun out from BDC, investing in cellular and targeted therapies plus AI applied to healthcare. Cheques of $5M to $30M CAD from company creation through Series B, mostly as lead, with strong reserve capacity to build companies over a decade. Fund II ($263M CAD), closed in 2024, brings assets above $500M CAD, with offices in Montreal, Toronto and Calgary. An operating partner for scientific founders who want to navigate clinical phases in Canada with a long-term capital partner anchored in Canadian institutions.
What they bring past the cheque
- Clinical strategy
- Deep biotech network
- Long-horizon capital
- Operator partners
Questions they usually ask
Have an answer ready for each one before the first call.
- How does Amplitude support founders through pre-clinical to Phase 1/2 transitions?
- What balance does the firm strike between cell/targeted therapy bets and AI for healthcare?
- What is the typical syndicate Amplitude leads or joins for Canadian biotech rounds?
Follow-on
Amplitude reserves heavy follow-on capacity inside its $263M Fund II to support portfolio companies through multiple clinical milestones.
Who to talk to
- Jean-François PariseauCo-Founder & Managing PartnerLinkedIn ↗
- Dion MadsenCo-Founder & Managing PartnerLinkedIn ↗
- Bharat SrinivasaPartnerLinkedIn ↗
- Allison GawPartnerLinkedIn ↗
- Michael MeePartnerLinkedIn ↗
- Matthew RosenbergerPartner & CFOLinkedIn ↗
Portfolio
Names they back, most notable first.
- RIME TherapeuticsSeed · 2026
- Mediar TherapeuticsSeries B+ · 2026
- EvommuneExit · 2025
- Congruence TherapeuticsSeries A
- Abdera TherapeuticsSeries B+
- Thryv TherapeuticsSeries A
- Notch TherapeuticsExit · 2025
- Valence LabsExit · 2023
Often in the same rounds
Investors seen alongside them in past rounds.
- OrbiMed
- Lumira Ventures
- Fonds de solidarité FTQ
- Investissement Québec
- BDC Capital
- Dimension
- ICG
- Longwood Fund
- Asahi Kasei Pharma Ventures
- Alexandria
- Driehaus
- Silver Arc
- CQDM
Similar investors
Overlapping sectors and stages. Useful to build a list of 10 to 20 names for one round.
See how they fit your round
Set your stage, sector and amount once. Fractal App tells you if Amplitude Ventures can lead it, tracks every follow-up, and counts the days of silence. Free, no card.
Open in the app →